Basal insulin in the age of innovation: are diamonds still forever?

While modern therapies are increasingly prioritized due to superior efficacy, safety, and weight benefits, basal insulin remains indispensable for patients with advanced β-cell failure, symptomatic hyperglycemia, or contraindications to newer agents. Personalized, pathophysiology-driven strategies should guide therapy selection, including the integration of basal insulin where appropriate.